Celsius Resources intends to join AIM. Currently ASX listed, Celsius is a natural resources exploration and development company principally seeking to explore and develop potential world-class copper-gold assets in the Philippines and a cobalt asset in Namibia. Amount planning to raise and anticipated market cap TBC. Expected late January 2023.
Conviction Life Sciences, a newly established closed-ended investment company managed by Plain English Finance Limited, is seeking to list on Premium Segment of the Main Market of the London Stock Exchange, to invest in a conviction portfolio of life sciences and medical technology businesses, primarily in the UK, Europe and Australasia. The Company will invest in both Publicly Traded and Private companies - c. 70% and c. 20% of the total portfolio value respectively. The Company will target an annualised Total NAV Return of 20% over the long-term. Targeting to raise c.£100m. Delayed to 3rd February 2023.
AB Dynamics £16.00 £366.2m (ABDP.L)
The designer, manufacturer and supplier of advanced testing, simulation and measurement products to the global transport market, issues a trading update, to coincide with the Company's Annual General Meeting taking place later today. The Board reports that performance over the first four months of FY 2023 has been in line with its expectations. The Group has a solid order book, providing good visibility into the second half of the year, and the integration of Ansible Motion is progressing as planned. Net cash at 31 December 2022 was £17.6m (31 December 2021: £27.4m, 31 August 2022: £29.2m), after payment of the initial £16.0m cash consideration for the acquisition of Ansible Motion in September 2022. Expectations for FY 2023 are unchanged.
Cambridge Cognition 121.5p £37.9m (COG.L)
The Company which develops and markets digital solutions to assess brain health, announces the acquisition of Winterlight Labs Inc, a leader in monitoring cognitive impairment through free-speech analysis. The total consideration for the Acquisition is £7m, comprising a cash payment of £3m and £4m in Cambridge Cognition shares. The cash consideration of £3m is being funded from the Company's existing cash resources, which were approximately £8.3m as of 31 December 2022. For the year ended 31 December 2022, Winterlight generated revenue of £1m and reported a loss before tax of £2.1m. Winterlight's gross assets are approximately £0.7m. Winterlight had a contracted order book of £2.5m as of 31 December 2022, with approximately 35% expected to be recognised as revenue in 2023.
Cornerstone Fs 7.25p £3.8m (CSFS.L)
The cloud-based provider of international payment, currency risk management and electronic account services to SMEs, provides an unaudited update on trading for the year ended 31 December 2022. As noted in the trading update announcement on 17 November 2022, the Group expected total revenue for 2022 of £4.3m. The Group now expects to report total revenue for 2022 of approximately £4.8m, representing 109% growth over 2021 and being 12% ahead of market expectations. The strong trading at the end of the year was across the Group's business. Accordingly, the growth in revenue for the year continues to be driven by clients that the Group serves directly, which is expected to account for approximately 78% of total revenue (2021: 56%) , and gross margin is expected to improve to approximately 61% for 2022 compared with 52% for 2021.
Deltic Energy 2.85p £53.1m (DELT.L)
The natural resources investing company with a high impact exploration and appraisal portfolio focused on the Southern and Central North Sea, announces that Shell, the Operator of exploration well 41/05a-2 on Licence P2252 (Shell 65%, Deltic 30%, ONE-Dyas 5% Working Interests), in the Southern North Sea has reported that gas has been encountered in the reservoir and has recommended to the Joint Venture (JV) that a full well testing programme be undertaken. The JV has endorsed the Operator's recommendation to undertake a full well test to evaluate the commerciality of the Pensacola prospect and update the geological model. Deltic will provide a drilling update announcement in respect of Pensacola on completion of well testing which is expected to take approximately 30 days.
Kibo Energy* 0.12p £3.6m (KIBO.L)
The renewable-energy-focused development company announces the appointment of Ajay Saldanha as an independent non-executive director to its Board of Directors with immediate effect. Ajay Dominic Saldanha is an experienced banking and investment professional with more than 20 years of experience in the power, energy and utilities sector. Furthermore, KIBO announces the appointment of Beaumont Cornish Limited as the Company's Nominated Adviser with immediate effect. Accordingly, the Company will resume trading on AIM from 7.30am today. With regard to the bridge loan facility announced on 16 February 2022, the Company has subsequently agreed with the Institutional Investor to extend the repayment date of said Facility to the 28 April 2023. As part of this agreement, the Company has provided the Institutional Investor with the right to trade shares held by it in Mast Energy Developments Plc up to the value of £250k the proceeds of which would be set off against the total amount owed under the Facility, being approximately £1.1m.
Nichols £10.83 £394.8m (NICL.L)
The diversified soft drinks Group, announces the appointment of Elizabeth (Liz) McMeikan as the Company's next Non-Executive Chair. Elizabeth will initially join the Group as a Non-Executive Director on 1st February 2023 before becoming Non-Executive Chair on 26th April 2023; that being the date of Nichols plc's 2023 Annual General Meeting. As announced on 27 April 2022, John Nichols stated his intention to retire as Non-Executive Chairman once a suitable replacement had been identified and appointed. He will therefore step down from the role following the Group's 2023 AGM. Elizabeth brings a wealth of consumer-focused public and private company experience to the Board from a number of non-executive board roles, further to an executive career spent with Colgate Palmolive and Tesco.
Physiomics* 4.2p £4.1m (PYC.L)
The consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, announces that it has entered into a further contract with its existing client Cancer Research UK. This represents the second such directly contracted project following the award completion last month of a contract for PKPD (pharmacodynamics, what the drug does to the body) modelling relating to the Cancer Research UK-sponsored clinical trial of AL ETA-001, a CAR-T cell engager candidate for the treatment of blood cancers developed by Aleta Biotherapeutics. The project is expected to be completed during Q1 2023.
WANdisco 917.5p £614.2m (WAND.L)
The data activation platform, announces a trading update for the 12 months ended 31 December 2022. Unaudited revenues are expected to be no less than $24m, growth of 229% year on year (FY21: $7.3m). Bookings in FY22 grew 967% to $127m (FY21: $11.9m). This record level was driven by significant progress in the Internet-of-Things (IoT) industry vertical with a majority of contract wins under the Group's commit-to-consume revenue model. The Company ended the period with cash of approximately $19m and $44m in trade receivables as at 31 December 2022. Taken together with a Remaining Performance Obligations of $110m this should see the Company through to profitability.
Warpaint London 187.5p £143.9m (W7L.L)
The specialist supplier of colour cosmetics and owner of the W7 and Technic brands is pleased to announce a trading update for the year ended 31 December 2022. The Company reports sales for the full year have exceeded previous expectations and are expected to be approximately £64m. In addition, in its full year results, the Group expects to report adjusted EBITDA of approximately £11.8m (2021: £7.6m) and adjusted profit before tax of approximately £10m (2021: £6.9m), both of which are ahead of current market expectations and the board's previous guidance for adjusted profit before tax. Cash balances as at 31 December 2022 totalling £5.8m (31 December 2021: £4.1m) and no debt.
Wishbone Gold 4.9p £10m (WSBN.L)
The gold and precious metals exploration company announces that it has acquired 100% of tenement application E45/ 6456 (Cottesloe East) covering 19 blocks (62km2) in the Paterson Range, Western Australia. The Cottesloe East tenement is contiguous to the Cottesloe Project (E45/4543) which is already owned by Wishbone, and brings the total project area to 50 blocks covering an area of 165km2. This has been acquired by staking the ground for a total cost of A$50k. Continued internal assessment of the Cottesloe prospect led to examination of the prospectivity of Cottesloe East. Wishbone Gold will combine the data sets from both prospects and work towards an expanded exploration program, subject to Heritage consents. Thus far the analysis suggests that the established anomalies on Cottesloe extend into Cottesloe East.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@chrish351.sg-host.com with “unsubscribe me”.
